Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vicriviroc · 8 trials · 4 indications
Objective response rate (ORR) was defined as the percentage of participants who experienced a complete response (CR; disappearance of all target lesions) or a partial response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by the investigator. ORR was estimated and analyzed using Clopper-Pearson interval.
DLTs were assessed during the first cycle (21 days) \& were defined as: Grade (Gr) 4 nonhematologic toxicity; Gr 4 hematologic toxicity lasting ≥7 days, except thrombocytopenia, Gr 4 thrombocytopenia of any duration, Gr 3 thrombocytopenia associated with bleeding; nonhematologic adverse event (AE) ≥ Gr 3 (with exceptions); Gr 3 or 4 nonhematologic lab abnormality (if medical intervention was required, lead to hospitalization, or persisted for \>72 hours); Gr 3 or 4 febrile neutropenia; inability to receive ≥75% of the planned vicriviroc dose because of drug-related tolerability; drug-related toxicity that caused a \>2 week delay in Cycle 2 initiation; elevated aspartate aminotransferase or alanine aminotransferase lab value that is \>3× upper limit of normal (ULN) \& an elevated total bilirubin value \>2× ULN \& an alkaline phosphatase value \<2× ULN, in which no alternative reasons were found.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued treatment due to an AE was assessed
HIV RNA was measured by AMPLICOR HIV-1 MONITOR Standard assay. For participants who had HIV RNA below the lower quantification of the Standard assay (LOQ of 400 copies/mL), the AMPLICOR HIV-1.5 UltraSensitive assay was performed. If the HIV RNA measurement was below the lower quantification of the UltraSensitive assay (LOQ of 50 copies/mL), a value of 49 was imputed. If a continuing participant has a missing HIV RNA value at the time point of interest, the geometric mean of immediately preceding and following values was used. If the participants had no subsequent following value or discontinued study treatment before the time point of interest, then the change from baseline was set to zero. Analysis was performed with a variance (ANOVA) model that adjusted for the treatment and stratification factors (intended enfuvirtide (T20) use in current newly-optimized background regimen (OBT) (Y/N) and HIV RNA at Screening (\> or ≤100,000 copies/mL)).
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment.
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment.
An SAE is any adverse occurrence that results in death; is life-threatening; results in a persistent disability; requires in-patient hospitalization or prolongs hospitalization; or is a congenital anomaly/birth defect.
The percentage of participants with HIV RNA \<50 copies/mL at each time point is reported. For this measure, "month" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.
The percentage of participants with HIV RNA \>50 to \<400 copies/mL at each time point is reported. For this measure, "month" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.
The percentage of participants with HIV RNA ≥400 copies/mL at each time point is reported. For this measure, "month" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.
The number of participants with non reportable (NR) tropism, CCR5 (R5) tropism, or dual/mixed CCR5/CXCR4 (DM/X4) tropism at baseline, who had NR, R5, or DM/X4 tropism at the time of virologic failure (VF) is reported. The definition of VF is an increase in HIV RNA level \>0.5 log10 copies/mL compared to the baseline HIV RNA level.
The mean change from baseline in CD4/CD8 counts throughout P4100 until the time of VF is reported. "Month" was defined as each 28-day period on study treatment. A fluorescent-activated cell sorter (FACS) analysis was used to quantify CD4/CD8 lymphocytes. The definition of VF is an increase in HIV RNA level \>0.5 log10 copies/mL compared to the baseline HIV RNA level.
The total number of participants with viruses having phenotypic resistance to VCV is reported. Viruses exhibiting both maximum percent inhibition (MPI) plateau values of \<85% and relative MPI (R-MPI) values of \<0.9 (based on the PhenoSense HIV entry assay) were considered to have phenotypic resistance to VCV.
The number of participants with ADEs is reported. An ADE is an SAE that is expected in the course of disease and not considered related to study intervention. The sponsor identified events that met ADE criteria based on the 1993 Centers for Disease Control (CDC) Revised Classification System.
The number of participants with new infections is reported.
| Arm | Type | Description |
|---|---|---|
| Test Arm | EXPERIMENTAL | Vicriviroc 30 mg QD |
| Placebo Control Arm | PLACEBO_COMPARATOR | Placebo |
| Vicriviroc QD at Dose Level 1 (150 mg) + Pembrolizumab (200 mg) | EXPERIMENTAL | Participants receive vicriviroc 150 mg tablets per os (PO) every day (QD) of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute intravenous (IV) infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days). |
| Vicriviroc QD at Dose Level 2 (250 mg) + Pembrolizumab (200 mg) | EXPERIMENTAL | Participants receive vicriviroc 250 mg tablets PO QD of each 21-day cycle up to 35 cycles and pembrolizumab 200 mg as a 30-minute IV infusion on Day 1 of each 21 day cycle up to 35 cycles (cycle length: 21 days). |
| Vicriviroc + Reyataz + ritonavir | EXPERIMENTAL | vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD |
| Truvada® + Reyataz + ritonavir | ACTIVE_COMPARATOR | Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD |
| 1 | EXPERIMENTAL | Vicriviroc 30 mg QD |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Double-Blind - Vicriviroc 30 mg | EXPERIMENTAL | Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized antiretroviral therapy (ART) regimen containing a ritonavir-boosted protease inhibitor (PI/r) for 48 weeks. |
| Double-Blind - Vicriviroc 20 mg | EXPERIMENTAL | Vicriviroc 20 mg QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks. |
| Double-Blind - Placebo | PLACEBO_COMPARATOR | Placebo QD, PO, plus an open-label optimized ART regimen containing a PI/r for 48 weeks. |
| Open-label - Vicriviroc 30 mg | EXPERIMENTAL | Vicriviroc 30 mg once daily (QD), orally (PO), plus an open-label optimized ART regimen containing a ritonavir-boosted protease inhibitor (PI/r) for up to 45 months. |
| VCV 30 mg | EXPERIMENTAL | Participants take VCV 30 mg once daily. |
| VCV + Failing HAART | EXPERIMENTAL | Vicriviroc plus failing highly-active antiretroviral therapy |
| Name | Type | Description |
|---|---|---|
| Vicriviroc | DRUG | One tablet of vicriviroc 30 mg once daily. |
| Placebo | DRUG | One tablet of placebo once daily. |
| Pembrolizumab | BIOLOGICAL | Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1. |
| emtricitabine and tenofovir disoproxil fumarate | DRUG | one 200/300 combination tablet QD |
| Vicriviroc 30 mg | DRUG | Three tablets of vicriviroc 10 mg once daily for 48 weeks (Double-blind Period) or for up to 45 months (Open Label Period). |
| Vicriviroc 20 mg | DRUG | Two tablets of vicriviroc 10 mg once daily for 48 weeks. |
| Background ART Regimen | DRUG | An open-label ritonavir-boosted optimized background ART regimen containing ≥3 drugs (including a protease inhibitor \[PI\]) selected for each individual study participant by the investigator. The optimized regimens most commonly include new nucleoside analogs (NRTIs) and a PI, usually "boosted" with concomitant ritonavir. |
| Vicriviroc maleate | DRUG | VCV 30 mg tablet once daily by mouth. |
Inclusion Criteria: * Subject must be infected with HIV-1 virus. * Subject must have documented plasma HIV-1 RNA \>1000 copies/mL within 60 days of Visit 1/Day 1 (randomization) and must be either * on a stable regimen of 3 or more antiretrovirals (ART) for at least 4 weeks prior to the screeni...
Top 20 of 28 competitors
Vicriviroc is an investigational small molecule being studied for HIV infections and colorectal neoplasms. In clinical trials, it has been evaluated in combination with optimized antiretroviral therapy for HIV and with pembrolizumab for advanced or metastatic microsatellite stable colorectal cancer. It is not approved and remains in clinical development.
Vicriviroc is a small molecule that targets the CCR5 receptor, which is involved in HIV entry into cells. By blocking this receptor, it aims to prevent the virus from infecting immune cells. This mechanism is relevant to its use in HIV treatment.
Vicriviroc is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker MRK. Merck has sponsored clinical trials of the drug across multiple indications.
Vicriviroc is in Phase 2 clinical development. It has completed Phase 2 trials for HIV infections and colorectal cancer, as well as a Phase 1 trial for HIV. The drug is investigational and has not received FDA approval.
Vicriviroc has been studied in six completed clinical trials. Key trials include NCT00243230 for HIV, NCT00632073 for HIV in cerebrospinal fluid, NCT00686829 as a rollover study for HIV, and NCT03631407 for colorectal cancer. All trials are completed with no active studies.
Yes, Vicriviroc is also known as SCH 417690 and MK-7690. These alternative names appear in clinical trial titles and protocols, such as NCT00243230 and NCT03631407, where the drug is referred to by these identifiers.